AbbVie Inc. (LON:0QCV)

Market Cap	306.63B
Revenue (ttm)	42.57B
Net Income (ttm)	2.72B
Shares Out	n/a
EPS (ttm)	1.53
PE Ratio	112.84
Forward PE	17.74
Dividend	4.99 (2.06%)
Ex-Dividend Date	Jul 15, 2025

Volume	8,513
Average Volume	4,606
Open	226.75
Previous Close	229.89
Day's Range	228.66 - 242.72
52-Week Range	159.76 - 242.63
Beta	0.53
RSI	69.65
Earnings Date	Oct 29, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD